Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets originated by precision oncology & validated by clinical trials & regulatory approval. RAD101, an 18F radioisotope developed to image brain metastases is the most advanced asset. It has advanced to Phase II clinical trials. Other candidates and their target include RAD 202 (HER2) & RAD204 (anti-PD-L1) which are both nanobodies conjugated to 177Lu for treatment. The pipeline further contains RAD301/302, a theranostic pair targeting aV 6 & preclinical assets targeting B7H3 (RV01) & KLK3 (RAD402). The company is developing candidates both in the US & developed global markets. It collaborates with Lantheus Holdings, MD Anderson (Radiopharm Ventures) & with CROs GenesisCare and MedPace.
